leon-nanodrugs strengthens its management team
leon-nanodrugs GmbH announced today, that in order to translate its strong technological position into commercial success, leon-nanodrugs is strengthening its drug development and financial management by expanding the management team to include:
Andrea Cusack, who has 25 years of experience in the pharmaceutical industry and held leading technical and commercial roles in worldwide operating companies at GSK, West Pharmaceutical Services, Archimedes and most recently Catalent, a global leader in the CMO/CDMO business.
She joined leon-nanodrugs in June 2018 and takes up the role of Managing Director & Chief Business Officer (CBO) of leon-nanodrugs. The CBO position combines commercial and operational responsibility and Andrea will work closely with Christian Nafe, CFO to manage operational activities for existing and new projects.
Christian Nafe, who has 25 years of experience in corporate finance, controlling and finance as well as held leading management positions in worldwide operating companies. Christian has served as CEO/CFO at several Biotech entities. Christian joined leon in February 2018. Additionally to his role as Chief Financial Officer (CFO), Christian became now Managing Director of leon-nanodrugs. His entrepreneurial skills together with his international financial expertise will be a significant contribution to achieve the next evolution step of the company.
Dr. Hubert Birner, Chairman of the Supervisory Board said, “The entire leon-nanodrugs team together with the leon-nanodrugs Board of Investors is convinced that this reinforcement of the management will lead to a sustainable market success of “leon-nanodrugs”
leon-nanodrugs GmbH is at the forefront of innovation providing solutions for the pharmaceutical development of poorly water-soluble drugs for oral and parenteral application forms, based on its proprietary, unique MJR nanotechnology platform. The company offers access to next generation nano-formulated drugs with meaningful differentiation and added patient benefits.